莫沙必利联合文拉法辛治疗功能性消化不良的疗效研究

目的 探讨莫沙必利联合文拉法辛治疗功能性消化不良的疗效.方法 收集2008年1月～2012年1月间我院入院治疗的功能性消化不良患者共76例,按照入院顺序分为观察组和对照组各38例.两组均予莫沙必利片5 mg,早、中、晚餐前30 min口服;观察组同时予文拉法辛缓释片75 mg早餐前服.疗程8周.比较两组的疗效及两组患者治疗前后HAMA评分、HAMD评分的变化及不良反应情况.结果 观察组的显效率达31.6%,总有效率达94.7%,对照组显效率达21.1%,总有效率达73.7%,两组显效率比较差异不显著,两组治疗后的总有效率比较,差异有统计学意义（P ＜ 0.05）.两组患者的腹痛、恶心呕吐、烧心、食欲不振的临床症状积分治疗后较治疗前明显降低,且观察组较对照组降低更显著,差异有统计学意义（P ＜ 0.05）.两组的HAMA评分、HAMD评分治疗后均较治疗前明显降低,且观察组较对照组降低更显著,差异有统计学意义（P ＜ 0.05）.治疗前后两组患者的肝肾功能及血尿常规未见明显异常.结论 莫沙必利联合文拉法辛治疗功能性消化不良疗效确切,安全性好,能够明显提高疗效,改善患者的临床症状及伴随的焦虑、抑郁症状,值得推广和应用.

The efficacy of mosapride combined with venlafaxine in the treatment of functional dyspepsia

Objective To explore the effect of mosapride joint venlafaxine treatment of functional dyspepsia. Methods A total of 76 cases collected from January 2008 to January 2012 in our hospital hospitalization of patients with func- tional dyspepsia were divided into observation group and the control group, 38 cases in each group, in accordance with the order of admission. Both groups were treated the mosapride tablets 5 mg, as early as 30 minutes before lunch, and dinner orally; observation group at the same time I venlafaxine extended release tablets 75 mg before breakfast for 8 weeks. Compared two groups of patients before and after treatment HAMA score, HAMD score and adverse reactions. Results Markedly effective rate was 31.6% of the observation group, the total effective rate was 94.7%, markedly effec- tive rate was 21.1% of the control group, the total effective rate was 73.7%, two sets of significant efficiency difference was not significant, the total effective rate between the two groups after treatment; the difference was statistically signif- icant （P 〈 0.05）. The two groups of patients with abdominal pain, nausea, vomiting, heartburn, loss of appetite clinical symptom score after treatment, significantly lower than before treatment, and the observation group lowered than in the control group more significant, the difference was statistically significant （P 〈 0.05）. Two sets of HAMA score, HAMD score significantly lowered after treatment than before treatment, and the observation group lowered than in the control group decreased more significantly, the difference was statistically significant （P 〈 0.05）. Patients before and after treat- ment of liver, renal function and urine routine no obvious abnormalities. Conclusion The mosapride joint venlafaxine treatment of functional dyspepsia is exact, security, and could significantly improve the efficacy, improve the patient＇s clinical symptoms and the accompanying anxiety and depression symptoms, worthy of promotion and application.